Global Neutropenia Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Neutropenia Market was valued at $16.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.1% CAGR, to an estimated market size of $21.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global neutropenia market comprises the therapeutics and supportive care solutions used to manage neutropenia, a hematological condition defined by abnormally low levels of neutrophils. The scope includes treatments for chemotherapy-induced neutropenia (CIN), congenital neutropenia, and idiopathic forms, primarily utilizing granulocyte colony-stimulating factors (G-CSFs), antibiotics, and antifungal agents.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Neutropenia Market in the period 2025-30:
- The rising global cancer incidence is the primary driver, leading to increased utilization of myelosuppressive chemotherapy regimens.
- There is a significant market shift toward biosimilars for drugs like pegfilgrastim to improve cost-effectiveness and patient access.
- Development of long-acting injectables and next-generation biologics is enhancing patient adherence by reducing the frequency of hospital visits.
- Increasing adoption of prophylactic therapies is becoming standard clinical practice to prevent the onset of febrile neutropenia.
- The emergence of oral formulations and small molecule drugs is providing more accessible treatment options in remote or resource-limited regions.
- Advancements in precision medicine allow for personalized treatment regimens based on a patient's specific genetic risk profile for bone marrow suppression.
- Growing R&D investment is fueling a robust pipeline of non-G-CSF therapies and novel drug delivery strategies like self-administration kits.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia Pacific
- Rest of World
Segments
- Colony-Stimulating Factors (CSFs)
- Antibiotics
- Antifungals & Antivirals
- Other Treatments